FDA Alert Over Multiple Myeloma Trials With Pembrolizumab FDA Alert Over Multiple Myeloma Trials With Pembrolizumab

The FDA has issued a statement about the increased risk for death that was observed when pembrolizumab was added to multiple myeloma regimens in clinical trials.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news